MétaCan
Menu
Back to cohort
Record W4311463033 · doi:10.1093/brain/awac480

Clinical and MRI measures to identify non-acute MOG-antibody disease in adults

2022· article· en· W4311463033 on OpenAlexfundno aff
Rosa Cortese, Marco Battaglini, Ferrán Prados, Alessia Bianchi, Lukas Haider, Anu Jacob, Jacqueline Palace, Silvia Messina, Friedemann Paul, Jens Wuerfel, Romain Marignier, Françoise Durand‐Dubief, Carolina de Medeiros Rimkus, Dagoberto Callegaro, Douglas Kazutoshi Sato, Massimo Filippi, Maria A. Rocca, Laura Cacciaguerra, Àlex Rovira, Jaume Sastre‐Garriga, Georgina Arrambide, Yaou Liu, Yunyun Duan, Claudio Gasperini, Carla Tortorella, Serena Ruggieri, Maria Pia Amato, Monica Ulivelli, Sergiu Groppa, Matthias Grothe, Sara Llufriú, María Sepúlveda, Carsten Lukas, Barbara Bellenberg, Ruth Schneider, Piotr Sowa, Elisabeth Gulowsen Celius, Anne‐Katrin Proebstel, Özgür Yaldizli, Jannis Müller, Bruno Stankoff, Benedetta Bodini, Luca Carmisciano, Maria Pia Sormani, Frederik Barkhof, Nicola De Stefano, Olga Ciccarelli, C Enzinger, Ludwig Kappos, J Palace, Hugo Vrenken, Tarek Yousry

Bibliographic record

VenueBrain · 2022
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsnot available
FundersNovartis PharmaIdorsia PharmaceuticalsH. Lundbeck A/SUniversity College London Hospitals NHS Foundation TrustFondazione Italiana di Ricerca per la Sclerosi Laterale AmiotroficaSchweizerische Multiple Sklerose GesellschaftFundação de Amparo à Pesquisa do Estado do Rio Grande do SulChugai PharmaceuticalMedDay PharmaceuticalsMinistero della SaluteUniversity College LondonBundesministerium für Bildung und ForschungGuarantors of BrainMultiple Sclerosis Society of CanadaUCB PharmaArgenxConselho Nacional de Desenvolvimento Científico e TecnológicoMultiple Sclerosis SocietyEuropean Committee for Treatment and Research in Multiple SclerosisEli Lilly and CompanyBristol-Myers SquibbCelgeneFondazione Italiana Sclerosi MultiplaBiogenAlexion PharmaceuticalsMylanRosetrees TrustSanofiNational Institute for Health and Care ResearchMedical Research CouncilTeva Pharmaceutical IndustriesSanofi GenzymeUniversität Basel
KeywordsNeuromyelitis opticaMedicineMyelin oligodendrocyte glycoproteinMultiple sclerosisSpectrum disorderExpanded Disability Status ScaleAcute disseminated encephalomyelitisDiseaseWhite matterPathologyInternal medicineImmunologyMagnetic resonance imagingRadiologyExperimental autoimmune encephalomyelitisPsychiatry

Abstract

fetched live from OpenAlex

MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing for MOG antibodies is unavailable or shows uncertain results. We aimed to identify MRI and clinical markers that differentiate non-acute MOG-antibody disease from aquaporin 4 (AQP4)-antibody neuromyelitis optica spectrum disorder and relapsing remitting multiple sclerosis, guiding in the identification of patients with MOG-antibody disease in clinical practice. In this cross-sectional retrospective study, data from 16 MAGNIMS centres were included. Data collection and analyses were conducted from 2019 to 2021. Inclusion criteria were: diagnosis of MOG-antibody disease; AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis; brain and cord MRI at least 6 months from relapse; and Expanded Disability Status Scale (EDSS) score on the day of MRI. Brain white matter T2 lesions, T1-hypointense lesions, cortical and cord lesions were identified. Random forest models were constructed to classify patients as MOG-antibody disease/AQP4-neuromyelitis optica spectrum disorder/multiple sclerosis; a leave one out cross-validation procedure assessed the performance of the models. Based on the best discriminators between diseases, we proposed a guide to target investigations for MOG-antibody disease. One hundred and sixty-two patients with MOG-antibody disease [99 females, mean age: 41 (±14) years, median EDSS: 2 (0-7.5)], 162 with AQP4-neuromyelitis optica spectrum disorder [132 females, mean age: 51 (±14) years, median EDSS: 3.5 (0-8)], 189 with multiple sclerosis (132 females, mean age: 40 (±10) years, median EDSS: 2 (0-8)] and 152 healthy controls (91 females) were studied. In young patients (<34 years), with low disability (EDSS < 3), the absence of Dawson's fingers, temporal lobe lesions and longitudinally extensive lesions in the cervical cord pointed towards a diagnosis of MOG-antibody disease instead of the other two diseases (accuracy: 76%, sensitivity: 81%, specificity: 84%, P < 0.001). In these non-acute patients, the number of brain lesions < 6 predicted MOG-antibody disease versus multiple sclerosis (accuracy: 83%, sensitivity: 82%, specificity: 83%, P < 0.001). An EDSS < 3 and the absence of longitudinally extensive lesions in the cervical cord predicted MOG-antibody disease versus AQP4-neuromyelitis optica spectrum disorder (accuracy: 76%, sensitivity: 89%, specificity: 62%, P < 0.001). A workflow with sequential tests and supporting features is proposed to guide better identification of patients with MOG-antibody disease. Adult patients with non-acute MOG-antibody disease showed distinctive clinical and MRI features when compared to AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis. A careful inspection of the morphology of brain and cord lesions together with clinical information can guide further analyses towards the diagnosis of MOG-antibody disease in clinical practice.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.052
Threshold uncertainty score0.456

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.060
GPT teacher head0.444
Teacher spread0.384 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations38
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueBrainSame topicMultiple Sclerosis Research StudiesFrench-language works237,207